PositoAI/ US/ NeoGenomics, Inc.

NeoGenomics, Inc.

NasdaqCM: NEO · Healthcare

Positivity Index

#5,225 / 6,774

Global

#2,805 / 4,000

United States

Positivity Score

18,065

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

NeoGenomics, Inc. — Overview & Financial Snapshot

NeoGenomics, Inc. (NasdaqCM: NEO) is a Healthcare company, ranked #5,225 of 6,774 companies globally and #2,805 of 4,000 in United States on PositoAI, with a Positivity Score of 18,065. Its market capitalisation is ₹19,875.99 Cr ($2.11B), P/E ratio is -42.0 and P/B ratio is 2.68. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

P/B Ratio 2.68

P/E Ratio -42.0

D/E Ratio 0.57

ROE -6.33%

Owes vs Owns ? 0.42× Low $0.42 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-36.81$-0.39

Forward EPS ₹32.35$0.34

Beta 1.78

Market Cap ₹19,875.99 Cr$2.11B

What these numbers mean →

What does NeoGenomics, Inc. do?

What is NeoGenomics, Inc.'s P/E and P/B ratio?

NeoGenomics, Inc. has a P/E ratio of -42.0 and a P/B ratio of 2.68.

What is NeoGenomics, Inc.'s debt-to-equity ratio?

NeoGenomics, Inc. has a debt-to-equity ratio of 0.57.

How much does NeoGenomics, Inc. owe compared with what it owns?

NeoGenomics, Inc. owes $0.42 for every $1 it owns (balance sheet Jun 2026), which is low.

What is NeoGenomics, Inc.'s Positivity rank?

NeoGenomics, Inc. is ranked #5,225 of 6,774 companies globally and #2,805 of 4,000 in United States on PositoAI, with a Positivity Score of 18,065.

Does NeoGenomics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for NeoGenomics, Inc..

Where can I read the latest news about NeoGenomics, Inc.?

Recent headlines about NeoGenomics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does NeoGenomics, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of NeoGenomics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.